Zonegran
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout Zonegran
Zonegran is a approved stage product being developed by Eisai for Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT00215592. Target conditions include Epilepsy.
What happened to similar drugs?
20 of 20 similar drugs in Epilepsy were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00215592 | Approved | Completed |
| NCT00165828 | Approved | Terminated |
Competing Products
20 competing products in Epilepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| perampanel | Eisai | Phase 2 | 35 |
| Lacosamide | UCB | Phase 3 | 40 |
| Zonisamide + Placebo | Eisai | Phase 3 | 32 |
| Zonegran | Eisai | Approved | 35 |
| perampanel + perampanel | Eisai | Phase 1 | 29 |
| Perampanel + Placebo | Eisai | Approved | 35 |
| perampanel | Eisai | Approved | 35 |
| E2007 + Placebo | Eisai | Phase 2 | 35 |
| Placebo + Rufinamide | Eisai | Phase 3 | 40 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 35 |
| Perampanel Oral Tablet | Eisai | Approved | 43 |
| perampanel | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Zonisamide + Carbamazepine | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Approved | 43 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 29 |
| Perampanel | Eisai | Phase 2 | 35 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| zonisamide low dose group + zonisamide high dose group | Eisai | Approved | 43 |
| E2007 + E2007 + Placebo | Eisai | Phase 2 | 35 |